Диссертация (Эффекты гиперэкспрессии гена белка предшественника амилоида в нервных клетках дрозофилы и поиск антиамилоидогенных соединений), страница 14
Описание файла
Файл "Диссертация" внутри архива находится в папке "Эффекты гиперэкспрессии гена белка предшественника амилоида в нервных клетках дрозофилы и поиск антиамилоидогенных соединений". PDF-файл из архива "Эффекты гиперэкспрессии гена белка предшественника амилоида в нервных клетках дрозофилы и поиск антиамилоидогенных соединений", который расположен в категории "". Всё это находится в предмете "биология" из Аспирантура и докторантура, которые можно найти в файловом архиве СПбГУ. Не смотря на прямую связь этого архива с СПбГУ, его также можно найти и в других разделах. , а ещё этот архив представляет собой кандидатскую диссертацию, поэтому ещё представлен в разделе всех диссертаций на соискание учёной степени кандидата биологических наук.
Просмотр PDF-файла онлайн
Текст 14 страницы из PDF
2012. Т.217. № 2. С. 244-5035. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., BirdT.D., Hardy J., Hutton M., Kukull W., Larson E., Levy-Lahad E., Viitanen M., PeskindE., Poorkaj P., Schellenberg G., Tanzi R., Wasco W., Lannfelt L., Selkoe D., YounkinS. Secreted amyloid-protein similar to that in the senile plaques of Alzheimer's diseaseis increased in vivo by the presenilin 1 and 2 and APP mutations linked to familialAlzheimer's disease // Nature Medicine. 1996. № 2. С.
864-870.36. Davidsson P., Blennow K. Neurochemical dissection of synaptic pathologyin Alzheimer’s disease // Int Psychogeriatr. 1998. Т. 10. С. 11–23.37. Dodel R., Rominger A., Bartenstein P., Barkhof F., Blennow K., Förster S.,Winter Y., Bach J.P., Popp J., Alferink J., Wiltfang J., Buerger K., Otto M., Antuono P.,Jacoby M., Richter R., Stevens J., Melamed I., Goldstein J., Haag S., Wietek S., FarlowM., Jessen F.
Intravenous immunoglobulin for treatment of mild to moderateAlzheimer’s disease: a phase 2, randomized, double-blind, placebo-controlled, dosefinding trial // Lancet Neurol. 2013. № 12. С. 233–243.9038. Doody R. S. Therapeutic standards in Alzheimer disease // Alzheimer Dis.Assoc. Disord. 1999. Т. 13. С.
20–26.39. Dreses-Werringloer U., Lambert J.C., Vingtdeux Т., Zhao H., Vais H.,Siebert A., Jain A., Koppel J., Rovelet-Lecrux A., Hannequin D., Pasquier F.,Galimberti D., Scarpini E., Mann D., Lendon C., Campion D., Amouyel P., Davies P.,Foskett J.K., Campagne F., Marambaud P.A. Polymorphism in CALHM1 influencesCa2+ homeostasis, Abeta levels, and Alzheimer's disease risk // Cell. 2008. Т. 27. № 7.С. 1149-61.40. Masliah E., Mallory M., Alford M. Altered expression of synaptic proteinsoccurs early during progression of Alzheimer’s disease // Neurology.
2001. № 56. С.127-129.41. Eli Lilly and Company. Lilly announces detailed results of phase 3Solanezumab EXPEDITIONS studies following a presentation of the independentanalyses by the Alzheimer’s Disease Cooperative Study (ADCS) // Eli Lilly andCompany[online],http://newsroom.lilly.com/releasedetail.cfm?releaseid=711933.2012.42. Eli Lilly and Company. Lilly halts development of semagacestat forAlzheimer’s disease based on preliminary results of phase III clinical trials // Eli Lillyand Company [online], http://newsroom.lilly.com/releasedetail.cfm?ReleaseID=499794.2010.43.
Emilien G., Durlach C., Minaker K.L., Winblad B., Gauthier S., MaloteauxJ.-M. // Alzheimer Disease: Neuropsychology and Pharmacology. - Basel: BirkhauserVerlag, 2004& - 288 C.44. Carrasquillo M.M., Belbin O., Hunter T.A., Ma L., Bisceglio G.D., Zou F.,Crook J.E., Pankratz V.S., Sando S.B., Aasly J.O., Barcikowska M., Wszolek Z.K.,Dickson D.W., Graff-Radford N.R., Petersen R.C., Morgan K., Younkin S.G.Replication of BIN1 association with Alzheimer's disease and evaluation of geneticinteractions // J. Alzheimers Dis.
2011. Т. 24. № 4. С. 751-8.9145. Ferreira S.T., Klein W.L. The Aβ oligomer hypothesis for synapse failureand memory loss in Alzheimer’s disease // Neurobiol. Learn. Mem. 2011. № 96. С.529–543.46. Ferris S.H. Evaluation of memantine for the treatment of Alzheimer’sdisease // Expert Opin. Pharmacother. 2003. Т. 4. С. 2305–2313.47. Finckh U., van Hadeln K., Müller-Thomsen T., Alberici A., Binetti G.,Hock C., Nitsch R.M., Stoppe G., Reiss J., Gal A. Association of late-onset Alzheimerdisease with a genotype of PLAU, the gene encoding urokinase-type plasminogenactivator on chromosome 10q22.2 // Neurogenetics.
2003. Т. 4. № 4. С. 213-7.48. Finelli A., Kelkar A., Song H.-J., Yang H., Konsolaki M. A model forstudying Alzheimer’s AB42-induced toxicity in Drosophila melanogaster // Mol. Cell.Neurosci. 2004. Т. 26. № 3. С. 365–37549. Fossgreen A., Bruckner B., Czech C., Masters C.L., Beyreuther K., Paro R.Transgenic Drosophila expressing human amyloid precursor protein show gammasecretase activity and a blistered-wing phenotype // Proceedings of the NationalAcademy of Sciences of the United States of America. 1998. № 95. С. 13703-13708.50.
GalimbertiD.,FenoglioC.andScarpiniE.Inflammationinneurodegenerative disorders: friend or foe? // Curr Aging Sci. 2008. № 1. С. 30-41.51. Gao Y. and Pimplikar S.W. The γ-secretase- cleaved C-terminal fragmentof amyloid precursor protein mediates signaling to the nucleus // Proceedings of theNational Academy of Sciences of the United States of America. 2001. Т. 98. С. 1497914984.52. Gelinas D.S., DaSilva K., Fenili D., St George-Hyslop P., McLaurin J.Immunotherapy for Alzheimer's disease // Proc Natl Acad Sci U S A. 2004.
Т. 101.Suppl 2. С. 4657–62.53. Giacobini E. and Becker R.E. One hundred years after discovery ofAlzheimer’s disease. A turning point for therapy? // J. Alzheimers Dis. 2007. № 12. С.37–52.9254. Gilman S., Koller M., Black R.S. Clinical effects of Ab immunization(AN1792) in patients with AD in an interrupted trial // Neurology. 2005. Т. 64. С.1553–1562.55. Goedert M., Spillantini M. A century of Alzheimer's disease // NeurobiolAging.
1997. Т. 18. № 4. С. 351-7.56. Gowher H., Leismann O., Jeltsch A. DNA of Drosophila melanogastercontains 5-methylcytosine // The EMBO J. 2000. Т. 19. № 24. С. 6918-6923.57. Green R.C., Cupples L.A., Kurz A., Auerbach S., Go R., Sadovnick D.,Duara R., Kukull W.A., Chui H., Edeki T., Griffith P.A., Friedland R.P., Bachman D.,Farrer L. Depression as a risk factor for Alzheimer disease: the MIRAGE Study // ArchNeurol.
2003. Т. 60. № 5. С. 753-9.58. Green C., Levashina,E., McKimmie C., Dafforn T., Reichhart J.-M. andGubb D. The necrotic gene in Drosophila corresponds to one of a cluster of three serpintranscripts mapping at 43A1.2 // Genetics. 2000. № 156. С. 1117-27.59. Greeve I., Kretzschmar D., Tschape J.-A., Beyn A., Brellinger C.,Schweizer M., Nitsch R.M., Reifegerste R. Age-dependent neurodegeneration andAlzheimer-amyloid plaque formation in transgenic Drosophila // The Journal ofNeuroscience. 2004. N. 24. С. 3899-3906.60.
Grilli M., Ribola M., Alberici A., Valerio A. and Memo M. Identificationand characterization of a kappa B/Rel binding site in the regulatory region of theamyloid precursor protein gene // The Journal of Biological Chem- istry. 1995. № 270.С. 26774-26777.61.
Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration:lessons from the Alzheimer's amyloid beta-peptide // Nat Rev Mol Cell Biol. 2007. Т. 8.№ 2. С. 101-12.62. Hardy J., Selkoe D. J. The amyloid hypothesis of Alzheimer’s disease:progress and problems on the road to therapeutics. An updated summary of the amyloidhypothesis // Science.
2002. Т. 297. С. 353–356.63. Hardy J.A., Higgins G.A. Alzheimer’s disease: the amyloid cascadehypothesis // Science. 1992. № 256. С. 184–185.9364. Hardy J. Alzheimer disease: the amyloid cascade hypothesis: an update andreappraisal // J. Alzheimers Dis. 2006. № 9. С. 151–153.65. Hardy J. and Selkoe D.J. The amyloid hypothesis of Alzheimer’s disease:Progress and problems on the road to therapeutics. An updated summary of the amyloidhypothesis // Science. 2002.
№ 297. С. 353-356.66. Hardy J. Testing times for the “amyloid cascade hypothesis” // Neurobiol.Aging. 2002. № 6. С. 1073–1074.67. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease:progress and problems on the road to therapeutics. An updated summary of the amyloidhypothesis // Science. 2002. № 297.
С. 353–356.68. Hébert S.S., Horré K., Nicolaï L., Bergmans B., Papadopoulou A.S.,Delacourte A., De Strooper B. MicroRNA regulation of Alzheimer's Amyloid precursorprotein expression // Neurobiol Dis. 2009. Т. 33. № 3. С. 422-8.69. Hébert S.S., Horré K., Nicolaï L., Papadopoulou A.S., Mandemakers W.,Silahtaroglu A.N., Kauppinen S., Delacourte A., De Strooper B. Loss of microRNAcluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increasedBACE1/beta-secretase expression // Proc Natl Acad Sci U S A. 2008. Т. 105.
№ 17. С.6415-20.70. Henley D.B., May С.C., Dean R.A. and Siemers E.R. Development ofsemagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment ofAlzheimer’s disease // ExС. Opin. Pharmacother. 2009. № 10. С. 1657–1674.71. Hernández F., Gómez de Barreda E., Fuster-Matanzo A., Lucas J.J., AvilaJ. GSK3: a possible link between beta amyloid peptide and tau protein // ExС.
Neurol.2010. Т. 223. № 2. С. 322-5.72. Hippius H. The discovery of Alzheimer's disease // Dialogues Clin.Neurosci. 2003. Т. 5. № 1. С. 101–108.73. Huang W., Yu H., Sheng R., Li J., Hu, Y. Identification of pharmacophoremodel, synthesis and biological evaluation of N-phenyl-1-arylamide and Nphenylbenzenesulfonamide derivatives as BACE 1 inhibitors // Bioorg Med Chem.2008. Т. 16. С. 10190–10197.9474. Itoh T., Satou T., Nishida S., Tsubaki M., Hashimoto S., Ito H. Expressionof amyloid precursor protein after rat traumatic brain injury // Neurol Res. 2009. Т. 31.№ 1. С.
